DelveInsight has launched a new report on Adrenoleukodystrophy (ALD) Market Insights, Epidemiology, and Market Forecast-2030.
Adrenoleukodystrophy (ALD) is a rare, X-linked, genetic disorder in which mutations within the ABCD1 gene lead to the loss of function of adrenoleukodystrophy protein (ALDP). Based on clinical manifestation, ALD is classified into cerebral adrenoleukodystrophy (CALD), adrenomyelodystrophy (AMN), and Addison’s disease (AI). The disease affects mainly males (hemizygotes), but similar to other X-linked disorders, it is increasingly recognized that females (heterozygotes) may be clinically affected, as well.
Cerebral Adrenoleukodystrophy (CALD) is the most severe form of ALD, characterized by a breakdown of the protective sheath known as myelin, which surrounds and protects the nerve cells responsible for thinking and muscle control. The symptoms of CALD usually occur in early childhood and progress rapidly if untreated, leading to a severe loss of brain function and eventually death in most patients.
DelveInsight’s “Adrenoleukodystrophy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Adrenoleukodystrophy, historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
- In 2017, the total prevalent population of ALD in the 7MM was 55,242.
- The estimates show the highest diagnosed prevalence of ALD in the United States with 4,885 cases in 2017.
- In 2017, the prevalent population of ALD in the US was 19,371.
- Japan ranked second among the 7MM in terms of prevalent cases for ALD.
Key benefits of the Report
- Adrenoleukodystrophy Market report covers a descriptive overview and comprehensive insight of the Adrenoleukodystrophy epidemiology and Adrenoleukodystrophy market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
- Adrenoleukodystrophy market report provides insights on the current and emerging therapies.
- Adrenoleukodystrophy market report offers a global historical and forecasted market covering drug outreach in 7 MM.
- Adrenoleukodystrophy market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Adrenoleukodystrophy market.
Request for Sample Pages: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market
“DelveInsight’s epidemiology model for ALD estimates that out of the total population of 19,371 cases in the US for ALD, 7,750 cases and 11,621 cases were contributed by males and females, respectively.”
Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity.
The disease mainly affects males (hemizygotes), but similar to other X-linked disorders, it is increasingly recognized that females (heterozygotes) may be clinically affected as well.
The main neurological manifestations include a progressive, fatal, inflammatory cerebral leukodystrophy (cerebral adrenoleukodystrophy) most frequently appearing in young boys, and a slowly progressive, non-inflammatory axonal myelopathy and peripheral neuropathy (adrenomyeloneuropathy, AMN), that occurs in most adult males. Many females develop myeloneuropathy as well, but usually at a later stage and with milder symptoms than seen in males. Furthermore, the disorder manifests with primary adrenal failure (PAI) in more than half of the males that are usually not seen in females.
There are three basic forms of ALD:
- Neonatal
- Childhood
- Adult-Onset
Request a free sample report @https://www.delveinsight.com/sample-request/adrenoleukodystrophy-market
“According to the DelveInsight’s Analysts, the market size of ALD was USD 922.43 million in 2017.”
Some of the key companies working on Adrenoleukodystrophy are:
- Bluebird Bio
- Minoryx Therapeutics
- MedDay Pharmaceuticals
- Magenta Therapeutics
- SOM Biotech
- Orpheris Inc.
The launch of the emerging therapies is expected to significantly impact the Adrenoleukodystrophy treatment scenario in the upcoming years:-
Drugs Covered:
- Lenti D
- Leriglitazone
- MD1003
- MGTA-456
- SOM1201
- OP-101
Table of Contents:
1. Key Insights
2. Executive Summary of Adrenoleukodystrophy (ALD)
3. Adrenoleukodystrophy (ALD): Market Overview at a Glance
4. Adrenoleukodystrophy: Disease Background and Overview
5. Patient Journey
6. Epidemiology and Patient Population
7. United States Epidemiology
8. EU5 Epidemiology
9. Japan Epidemiology
10. Current Treatment and Medical Practices
11. Unmet Needs
12. Emerging Therapies
13. Failed Therapy
14. Adrenoleukodystrophy (ALD): 7MM Market Analysis
16. United States
17. EU-5 countries
18. Japan
19. Market Drivers
20. Market Barriers
21. Market Access and Reimbursement
22. SWOT Analysis
23. Appendix
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight
Read more on Adrenoleukodystrophy Market @https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
Related Reports:
1. Adrenoleukodystrophy Pipeline Insights, 2020
2. Adrenoleukodystrophy (ALD) Epidemiology Forecast to 2030
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/